Literature DB >> 29458779

Systemic treatment in adult uterine sarcomas.

I M E Desar1, P B Ottevanger1, C Benson2, W T A van der Graaf3.   

Abstract

Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma (HG-ESS), adenosarcomas and high grade undifferentiated sarcoma (HGUS). US are often high-grade tumours with a high local recurrence rate and metastatic risk. We here discuss the current standard of care and knowledge of systemic therapy for adult uterine sarcomas, in particular uLMS, LG-ESS, HG-ESS and HGUS, in both the adjuvant as well as the metastatic setting.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Hormone therapy; Systemic treatment; Targeted therapy; Uterine sarcoma

Mesh：

Year:  2017        PMID： 29458779     DOI： 10.1016/j.critrevonc.2017.12.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  10 in total

1.  PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma.

Authors:  Siming Gong; Nikolas Schopow; Yingjuan Duan; Changwu Wu; Sonja Kallendrusch; Georg Osterhoff
Journal:  Genes (Basel)       Date:  2022-04-28       Impact factor: 4.141

2.  An estrogen receptor-positive locally aggressive smooth muscle neoplasm of the transverse colon: A case report.

Authors:  Genki Usui; Hirotsugu Hashimoto; Kazuteru Watanabe; Yoshiya Sugiura; Masashi Kusakabe; Eiji Sakai; Yasushi Harihara; Hajime Horiuchi; Teppei Morikawa
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

3.  High-grade endometrial stromal sarcoma: a retrospective study of factors influencing prognosis.

Authors:  Yan-Yan Zhang; Yan Li; Meng Qin; Yan Cai; Ying Jin; Ling-Ya Pan
Journal:  Cancer Manag Res       Date:  2019-01-17       Impact factor: 3.989

Review 4.  Current status of the adjuvant therapy in uterine sarcoma: A literature review.

Authors:  Alessandro Rizzo; Maria Abbondanza Pantaleo; Maristella Saponara; Margherita Nannini
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

5.  Construction and Validation of Nomograms for Predicting the Prognosis of Uterine Leiomyosarcoma: A Population-Based Study.

Authors:  Yue Meng; Yuebo Yang; Yu Zhang; Xiaomao Li
Journal:  Med Sci Monit       Date:  2020-04-09

6.  'I thought I had fibroids, and now I don't': a mixed method study on health-related quality of life in uterine sarcoma patients.

Authors:  Olga Husson; Winette T A van der Graaf; Dide den Hollander; Emma Lidington; Susanne Singer; Samantha C Sodergren; Samer Salah; Marco Fiore; Charlotte Benson; Ingrid M E Desar; Vivian W G Burgers
Journal:  Health Qual Life Outcomes       Date:  2022-04-20       Impact factor: 3.077

7.  The role of postoperative radiotherapy in patients with uterine sarcomas: A PSM-IPTW analysis based on SEER database.

Authors:  Zhimin Hao; Sufen Yang
Journal:  Front Surg       Date:  2022-08-09

8.  Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and Carcinosarcoma Prognosis and Treatment?

Authors:  Laura Gonzalez Dos Anjos; Bruna Cristine de Almeida; Thais Gomes de Almeida; André Mourão Lavorato Rocha; Giovana De Nardo Maffazioli; Fernando Augusto Soares; Isabela Werneck da Cunha; Edmund Chada Baracat; Katia Candido Carvalho
Journal:  Cancers (Basel)       Date:  2018-09-06       Impact factor: 6.639

9.  Unexpected Histopathological Diagnosis of Undifferentiated Uterine Sarcoma after Simple Hysterectomy: Extrapolating Limited Evidence.

Authors:  Amenda Ann Davis
Journal:  Cureus       Date:  2020-01-27

10.  Identification of uterine leiomyosarcoma-associated hub genes and immune cell infiltration pattern using weighted co-expression network analysis and CIBERSORT algorithm.

Authors:  Xiaoqing Shen; Zhujuan Yang; Songwei Feng; Yi Li
Journal:  World J Surg Oncol       Date:  2021-07-28       Impact factor: 2.754
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.